Treatment For Mood and Anxiety Disorders With Glutmatergic Agents

According to findings of a latest research disclosed in 26the ECNP, there are possibilities of using Glutmatergic agents for treatment of mood and anxiety disorders in near future. “Our results suggest the glutamtergic system is a truly viable target for antidepressant Profug development” said Professor Gerard Sanacore of Yale School of Medicine. The school is based at Connecticut in United States. Researching with animals he had arrived at the conclusion that stress and related mechanism could ultimately disrupt glutamatergic functions in human anatomy. Disruption of cellular and molecular structures in brain can create depression in man and woman. A second phase of research and analysis brought up the findings that drugs targeting glutamate transmissions have the ability to prevent such behavioral changes as they happen in course of mood disorders. Derivation of such theses was possible with the introduction of unique NMDA receptor antagonist that worked wonderfully well as antidepressant on human anatomy. “First and foremost, our findings suggest the glutamatergic system is a truly viable target for antidepressant drug development” concluded Prof. Sannacora.